IP Library Granted Patent US 12,365,698
Granted Patent B2
US 12,365,698 · App. 17/774,662 · Granted Jul 22, 2025

Application of boron dipyrromethene derivatives in anti-tumor and anti-bacterial therapy

Inventors: Benjamin Florian Hohlfeld (Berlin, DE); Arno Wiehe (Berlin, DE); Burkhard Gitter (Jena, DE); Dorika Steen (Jena, DE); Gerhard Wieland (Jena, DE); Volker Albrecht (Nuthetal, DE)
Assignee: BIOLITEC UNTERNEHMENSBETEILIGUNGS III AG
C07F5/022A61K31/69A61K41/0057A61K47/64A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,698
App. No.
17/774,662
Granted
Jul 22, 2025
Kind
B2
Abstract

Biologically active compounds and their methods of preparation are provided that may be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of non-tumorous indications such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, otorhinolaryngology disorders, ophthalmological or urological disorders. As the compounds exhibit also toxicity against targets (tumor cells, bacteria, inflammation-related cells) without light these biologically active compounds may also be used for the light-independent treatment of such indications. Embodiments also include methods to synthesize boron dipyrromethene complex structures incorporating a substituted 2,3,5,6-tetrafluorophenyl-dipyrromethene (2,3,5,6-tetrafluorophenyldipyrrin) unit or a substituted 3-nitrophenyl-dipyrromethene (3-nitrophenyl-dipyrrin) unit. Amphiphilic compounds with increased anti-tumour and anti-bacterial efficacy are also provided. Specifically, this is achieved by substitution with bromine atoms and sugar moieties.

Claims (15)

1. A boron dipyrromethene compound based on the formulas 1, 2, 3 or 4:

Wherein:

X is at least one of O, NH or S;

R 1 is at least one of a carbohydrate moiety, a short alkyl chain with 3 to 6 carbon atoms, propargyl, HO—CH 2 —CH 2 —, CH(CH 2 OH) 2 , CH 2 —CH(OH)—CH 2 OH, or CH(OH)—CH(OH)—CH 3 ; and

R 2 is at least one of hydrogen or a bromine substituent (atom).

2. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable derivative thereof as an active ingredient.

3. The pharmaceutical composition of claim 2 , wherein the compound is conjugated to a targeting agent.

4. The pharmaceutical composition of claim 3 , wherein the targeting agent is a peptide.

5. A pharmaceutical composition comprising a compound according to claim 1 .

6. A method of treating a subject having a condition, selected from the group consisting of tumors, dermatological disorders, viral infections, bacterial infections, otorhinolaryngology disorders, ophthalmological disorders and urological disorders, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .

7. The method of claim 6 wherein the condition comprises a tumor.

8. The method of claim 6 further comprising administering photodynamic therapy to the subject.

9. The method of claim 7 further comprising administering photodynamic therapy to the subject.

10. A method of treating a subject having arthritis comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , further comprising administering photodynamic therapy to the subject.

11. A method of diagnosing arthritis in a subject comprising administering to the subject an effective amount of the compound of claim 1 and performing fluorescence diagnosis on the subject.

Assignments (2)
CHANGE OF NAME Recorded Aug 23, 2024
From: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS III AG
Reel/Frame 068381/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2024
From: HOHLFELD, BENJAMIN FLORIAN; WIEHE, ARNO; GITTER, BURKHARD; STEEN, DORIKA; WIELAND, GERHARD; ALBRECHT, VOLKER
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
Reel/Frame 066183/0466 →
Continuity (2)
Provisional Application 62930933 · Nov 5, 2019
Related Publication 20220380388A1 · Dec 1, 2022
References Cited (5)
Martinez et al. (ACS Infect. Dis. 2019, 5, 9, 1624-1633) (Year: 2019). [cited by examiner]
Correia Pharmaceutics. Sep. 2021; 13(9): 1332. (Year: 2021). [cited by examiner]
Hu. Journal of Nanobiotechnology. 2022; 20 (437) (Year: 2022). [cited by examiner]
Banfi Stefano et al: “Synthesis and photo-physical properties of a series of BODIPY dyes”, Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, vol. 69, No. 24, Apr. 18, 2013 (Apr. 18, 2013) pp. 4845-4856. [cited by applicant]
PCT Search Report and Written Opinion mailed on May 14, 2021 for PCT Application PCT/EP2020/081184, 5 pages. [cited by applicant]